» Articles » PMID: 11826411

NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2002 Feb 5
PMID 11826411
Citations 319
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic steatohepatitis (NASH) is often linked with disorders that are clearly associated with insulin resistance (IR): obesity, type 2 diabetes mellitus, and hypertriglyceridemia. We tested the hypotheses that (1) IR is an essential requirement for the development of NASH and (2) a high association between IR and liver disease is relatively specific for NASH. We measured body mass index (BMI), waist/hip ratio, and fasting serum lipid, insulin, C-peptide, and glucose levels in 66 patients with NASH (21 with advanced fibrosis and 45 with mild fibrosis). IR was determined by the homeostasis model assessment (HOMA). We also determined the strength of the association of NASH with insulin resistance syndrome (IRS) as defined by World Health Organization criteria. To assess whether the finding of IR was relatively specific to NASH rather than simply to obesity or liver disease, we compared the results of a subset of 36 patients with less-severe NASH with 36 age- and sex-matched patients with chronic hepatitis C virus (HCV) of comparable fibrotic severity. IR was confirmed in 65 patients (98%) with NASH, and 55 (87%) fulfilled minimum criteria for IRS. IR was found in lean as well as in overweight and obese patients. The IR values and the prevalence of IRS (75% vs. 8.3%) were significantly higher in those with NASH than in comparable cases of HCV. Hyperinsulinemia was attributable to increased insulin secretion rather than decreased hepatic extraction. In conclusion, most patients with NASH have IRS, and there is a near-universal association between NASH and IR irrespective of obesity. IR is present in mild as well as advanced cases of NASH but is unusual in chronic HCV of similar fibrotic severity.

Citing Articles

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).

Do A, Zahrawi F, Mehal W Nat Rev Drug Discov. 2024; 24(3):171-189.

PMID: 39609545 DOI: 10.1038/s41573-024-01084-2.


()-5-hydroxy-7-methoxy-3-(2-hydroxybenzyl)-4-chromanone, a Major Homoisoflavonoid, Attenuates Free Fatty Acid-Induced Hepatic Steatosis by Activating AMPK and PPARα Pathways in HepG2 Cells.

Park J, Han J Nutrients. 2024; 16(20).

PMID: 39458470 PMC: 11510552. DOI: 10.3390/nu16203475.


Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial.

Ishay Y, Neutel J, Kolben Y, Gelman R, Arbib O, Lopez O Gastro Hep Adv. 2024; 3(3):417-425.

PMID: 39131144 PMC: 11308786. DOI: 10.1016/j.gastha.2023.11.016.


Discriminating insulin resistance in middle-aged nondiabetic women using machine learning approaches.

Xing Z, Chen H, Alman A AIMS Public Health. 2024; 11(2):667-687.

PMID: 39027391 PMC: 11252584. DOI: 10.3934/publichealth.2024034.


Nonalcoholic Fatty Liver Disease as a Potential Risk Factor for Cardiovascular Disease in Patients with Type 2 Diabetes: A Prospective Cohort Study.

Dehghani Firouzabadi M, Poopak A, Sheikhy A, Dehghani Firouzabadi F, Moosaie F, Rabizadeh S Int J Endocrinol. 2024; 2024:5328965.

PMID: 38962375 PMC: 11221952. DOI: 10.1155/2024/5328965.